Skip to main content
Woman scientist working at lab bench

Intellectual Property
Securing the Future: Building a Strong IP Estate in RNAa and Oligonucleotide Delivery 

Intellectual Property

At the heart of Ractigen Therapeutics lies a strong intellectual property (IP) foundation, notably in the fields of RNA activation (RNAa) and oligonucleotide delivery. Central to our innovation is a high-throughput discovery engine, expertly designed for the swift identification of small activating RNAs (saRNAs). Our IP portfolio is strategically constructed upon both the composition of matter and methods of use, encompassing an expanding library of therapeutic oligonucleotides. The development of proprietary medicinal chemistries and delivery platforms, all created in-house, further solidifies our IP estate, providing a robust platform for advanced drug development


Our Discovery Engine

It features a highly-refined bioinformatics algorithm integrating epigenetic datasets, design rules, and genome-wide on-target prediction tethered to in-house oligonucleotide manufacturing for saRNA synthesis followed by automated experimental validation of saRNA activity.

Labeled arrows: Genetic Sequence, Target Identification, saRNA Synthesis, and HTS
Target Gene Locus icon

Target Gene Locus

Rapidly identify all saRNAs for any single target gene

Search Algorithm icon

Search Algorithm

bioinformatics algorithm

In-House Synthesis icon

In-House Synthesis

Oligonucleotide manufacturing for in-house saRNA synthesis

In vitro Screening & Gene Expression icon

In vitro Screening & Gene Expression

Automated rounds of dose-dependent gene expression

3-4 Weeks Start to Finish (All In-House)

Start to finish underline

Screen Hundreds of saRNA Candidates

Automated rounds of dose-dependent gene expression analytics and integrated de-risking safety assays allow for the screening of hundreds of saRNA candidates within 30-45 days.

Honing the Process

We are continually honing the process in pursuit of full-automation and continue to add to our ever-growing list of therapeutic genes expanding our IP estate and feeding our drug development pipeline.

Want to Discover More?

Check out our News. Below are some highlights to get you started.


May 21, 2024 in Homepage News, News Highlight, RAG-01

Ractigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA Therapy

SUZHOU, China, May 21, 2024 – Ractigen Therapeutics, a pioneering developer of small activating RNA…
Read More
May 15, 2024 in Company News, RAG-17

Ractigen Therapeutics Receives IND Approval from China’s NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients

JIANGSU, CHINA (May 15, 2024) – Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing…
Read More
April 26, 2024 in Company News, RAG-01

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…
Read More
April 3, 2024 in Company News, RAG-01

Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC

JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…
Read More